X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JK07 is a recombinant fusion protein consisting of a fully human immunoglobulin IgG1 monoclonal antibody, which is being evaluating in the mid-stage clinical trials for the treatment of patients with HFrEF and HFpEF.
Lead Product(s): JK07
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 22, 2024
Details:
The financing will be used to advance and accelerate JK07, including the planned initiation of the first Phase 2 study in HFrEF and the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction.
Lead Product(s): JK07
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD.
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 28, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
